PVI
CHRS icon

Pura Vida Investments’s Coherus Oncology CHRS Stock Holding History

Pura Vida Investments’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-97,500
Closed -$1.36M – 111
2018
Q2 		$1.36M Buy
+97,500
New +$1.4M 0.55% 60

Other funds holding CHRS

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Pura Vida Investments's CHRS Position: Q4 2019 in Review

Pura Vida Investments sold out of Coherus Oncology (CHRS) in Q4 2019, closing a stake of 50,000 shares — an estimated $1.01M sold.

Pura Vida Investments first reported a position in CHRS in Q4 2017 and held it in 5 quarters. The position peaked at $2.41M in Q2 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q4 2019.

  • Pura Vida Investments reported no remaining Coherus Oncology position as of Q4 2019 after selling out during the quarter.
  • Pura Vida Investments sold 50,000 Coherus Oncology shares in Q4 2019, an estimated $1.01M.
  • Pura Vida Investments first reported a position in Coherus Oncology in Q4 2017 and held it in 5 quarters.
  • Pura Vida Investments's Coherus Oncology position peaked at $2.41M in Q2 2019.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2019.

Based on Pura Vida Investments's 13F filing for Q4 2019, filed 14 Feb 2020.